Labcorp (LH)
(Delayed Data from NYSE)
$230.70 USD
+0.49 (0.21%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $230.88 +0.18 (0.08%) 7:48 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$230.70 USD
+0.49 (0.21%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $230.88 +0.18 (0.08%) 7:48 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
Should You Hold Labcorp (LH) Stock in Your Portfolio Now?
by Zacks Equity Research
Labcorp's (LH) slew of partnerships and acquisitions and robust efforts in high-growth areas bode well.
Labcorp (LH) Gains From New Collaborations Amid FX Issues
by Zacks Equity Research
Labcorp's (LH) Biopharma Laboratory Services business is benefiting from collaborations with leading pharmaceutical and biotechnology companies.
Labcorp (LH) Q2 Earnings Surpass Estimates (revised)
by Mark Vickery
Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.
Labcorp (LH) Q2 Earnings Surpass Estimates, Margins Increase
by Zacks Equity Research
Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.
Compared to Estimates, Labcorp (LH) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Labcorp (LH) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of 4.23% and 0.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 4 MedTech Stocks in Q2 Earnings?
by Urmimala Biswas
Here is a sneak peek into how four MedTech companies, LH, BIO, TFX and BRKR, are expected to fare in their second-quarter results, slated to be released tomorrow.
Earnings Preview: Henry Schein (HSIC) Q2 Earnings Expected to Decline
by Zacks Equity Research
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp (LH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align Technology (ALGN) Q2 Earnings Top Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 3.88% and 0.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's How Labcorp (LH) is Placed Ahead of Q2 Earnings Release
by Zacks Equity Research
Labcorp's (LH) second-quarter 2024 performance is expected to reflect the robust execution of strategic priorities and solid business performances.
Strength Seen in Henry Schein (HSIC): Can Its 5.4% Jump Turn into More Strength?
by Zacks Equity Research
Henry Schein (HSIC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Implied Volatility Surging for Labcorp (LH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Labcorp (LH) stock based on the movements in the options market lately.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Labcorp (LH) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is It the Right Time to Hold Labcorp (LH) in Your Portfolio?
by Zacks Equity Research
Labcorp's (LH) concentrated development in high-growth areas and strategic partnerships appear encouraging.
Why Labcorp (LH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Labcorp (LH) to Assess Preeclampsia Risk With New Test
by Zacks Equity Research
Labcorp's (LH) new first-trimester test is the latest addition to its dedication to improving women's health.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about Labcorp (LH), led by strategic acquisitions and strong expansion in the Biopharma Laboratory.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp
by Zacks Equity Research
10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp are included in this Analyst Blog.
Integer Holdings (ITGR) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect robust Medical Sales, along with strength in all the product lines.
3 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View
by Zacks Equity Research
Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.
Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.